While MSD brings the scientific excellence of the compound to the partnership, Sun Pharma brings its expertise in the marketing of drugs in the relevant therapeutic areas across India.
The partnership aims to enhance the reach of sitagliptin and sitagliptin plus metformin amongst doctors and patients in India.
MSD in India MD KG Ananthakrishnan said the partnership with Sun Pharma is focused on increasing the market access of sitagliptin & sitagliptin plus metformin in India, which is an urgent need, given the high disease burden of type 2 diabetes in India and the role of these drugs in helping to address the same.
MSD operates in India through three separate legal entities MSD Pharmaceuticals, Organon India and Fulford India, which are
subsidiaries of Merck & Co Inc USA.